Exane Derivatives’s Bed Bath & Beyond Inc BBBY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-67
Closed -$1.51K 1054
2022
Q1
$1.51K Hold
67
﹤0.01% 774
2021
Q4
$977 Hold
67
﹤0.01% 714
2021
Q3
$1.16K Hold
67
﹤0.01% 844
2021
Q2
$1.97K Buy
+67
New +$1.86K ﹤0.01% 819
2021
Q1
Sell
-67
Closed -$1.19K 974
2020
Q4
$1.19K Hold
67
﹤0.01% 666
2020
Q3
$1K Hold
67
﹤0.01% 618
2020
Q2
$710 Hold
67
﹤0.01% 585
2020
Q1
$282 Hold
67
﹤0.01% 643
2019
Q4
$1.04K Hold
67
﹤0.01% 544
2019
Q3
$713 Hold
67
﹤0.01% 561
2019
Q2
$778 Buy
+67
New +$993 ﹤0.01% 569
2019
Q1
Sell
-67
Closed -$758 718
2018
Q4
$758 Hold
67
﹤0.01% 582
2018
Q3
$1.01K Hold
67
﹤0.01% 544
2018
Q2
$1.33K Hold
67
﹤0.01% 513
2018
Q1
$1.38K Buy
+67
New +$1.48K ﹤0.01% 465
2017
Q2
Sell
-36,217
Closed -$1.43M 685
2017
Q1
$1.43M Buy
+36,217
New +$1.45M 0.32% 74
2016
Q2
Sell
-16,864
Closed -$837K 636
2016
Q1
$837K Buy
+16,864
New +$790K 0.11% 102
2015
Q2
Sell
-5,917
Closed -$454K 567
2015
Q1
$454K Sell
5,917
-37,383
-86% -$2.84M 0.05% 151
2014
Q4
$3.3M Buy
+43,300
New +$3.02M 0.46% 49

Other funds holding BBBY

Exane Derivatives's BBBY Position: Q2 2022 in Review

Exane Derivatives sold out of Bed Bath & Beyond Inc (BBBY) in Q2 2022, closing a stake of 67 shares — an estimated $1.51K sold.

Exane Derivatives first reported a position in BBBY in Q4 2014 and held it in 19 quarters. The position peaked at $3.3M in Q4 2014. 218 funds tracked by Wall St. Rank hold BBBY as of Q2 2022.

  • Exane Derivatives reported no remaining Bed Bath & Beyond Inc position as of Q2 2022 after selling out during the quarter.
  • Exane Derivatives sold 67 Bed Bath & Beyond Inc shares in Q2 2022, an estimated $1.51K.
  • Exane Derivatives first reported a position in Bed Bath & Beyond Inc in Q4 2014 and held it in 19 quarters.
  • Exane Derivatives's Bed Bath & Beyond Inc position peaked at $3.3M in Q4 2014.
  • 218 funds tracked by Wall St. Rank held Bed Bath & Beyond Inc as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.